ClinicalTrials.gg
Active, not recruitingNCT06550024SUREUpdated Oct 30, 2026

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

An interventional study of SakuraBead Resorbable Microspheres and Corticosteroid Injection in Osteo Arthritis Knee, Joint Diseases and Musculoskeletal Diseases, sponsored by CrannMed. Active, not recruiting at 8 sites in 4 countries. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionOsteoarthritisRegistry: Joint DiseasesReclassifiedWhy we changed it
Registry
Joint Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis
Why
  1. The study's listed conditions name Osteoarthritis, a narrower term within Joint Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CrannMed · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
40 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Planned enrollment
451st of 832
89 · median 100
Started
2024
with 16 others
No phase
437 of 1,029
54 open now
Primary completion
2026-12
later than 55 of 174 live
Registered
953rd of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 451st largest by planned enrollment of the 832 interventional ones that give a count, is one of 17 that started in 2024, is one of 437 with no phase, reaches primary completion later than 55 of the 174 other live ones, and was the 953rd registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 40 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

Read the detailed description

To compare safety and efficacy of SakuraBead with corticosteroid injection for the treatment of pain secondary to knee osteoarthritis. Treatment will be performed on a total of approximately 89 patients who will be followed up for a period of 2 years.

03

Conditions studied

  • Osteo Arthritis Knee
  • Joint Diseases
  • Musculoskeletal Diseases
  • Rheumatic Diseases
  • Arthritis
  • Osteoarthritis

Keywords

  • Genicular Artery Embolization
  • GAE
  • Knee Embolization
  • Knee OA
  • Knee Osteoarthritis
04

In context

Osteoarthritis Reclassified

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's planned enrollment of 89 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

CrannMed is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Osteoarthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Joint Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is able and willing to provide written , and
  2. Clinical diagnosis of knee OA, and
  3. Moderate to severe knee pain (WOMAC Pain ≥ 10), and
  4. Pain to at least 3 months of conservative therapies (anti-inflammatory drugs, or physical therapy, or intra-articular injections), and
  5. Kellgren-Lawrence grade 1, 2 or 3 on radiograph of the knee, and
  6. Age ≥ 40 years and \< 80 years, and
  7. Able to comply with all treatments and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Severe knee OA (Kellgren-Lawrence grade 4), or
  2. Current infection of target joint, or
  3. less than 36 months, or
  4. Known advanced atherosclerosis as defined by history of lower extremity or pelvis arterial bypass graft, lower extremity or pelvis arterial stent placement or prior history of vascular claudication, or
  5. Rheumatoid or known serologic diagnosis of arthritis, or
  6. Prior knee replacement surgery in the target knee, or
  7. Pain score of >3 NRS on the non-target knee, or
  8. An acute internal derangement of the target knee, or
  9. History of uncorrectable coagulopathy, or
  10. Prior iodinated contrast reaction resulting in anaphylaxis, or
  11. Active pregnancy as demonstrated by urine or serum β-hCG, or lactating female, or planning pregnancy in the following 12 months, or
  12. Has undergone an invasive treatment (including but not limited to: injection, hyaluronic acid injections, nerve ablation) in the target knee within the past 3 months, or
  13. to MRI, or
  14. At the discretion of the Principal Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (estimated)

Study arms

  • Experimental
    Genicular Artery Embolization (GAE)

    Temporary Embolization of Genicular Arteries using Resorbable Microspheres

    Device: SakuraBead Resorbable Microspheres

  • Active comparator
    Corticosteroid Injection

    Corticosteroid injection in the knee

    Drug: Corticosteroid Injection

Interventions

  • DeviceSakuraBead Resorbable Microspheres

    Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres

  • DrugCorticosteroid Injection

    Corticosteroid injection in the knee

07

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint - Proportion of Responders

    Compare the proportion of responders\* (defined as ≥50% reduction in WOMAC Pain\*\* score and ≥2 point reduction in NRS\*\*\*) between the Investigational procedure and Control at 6 months. * Non-responders will include subjects experiencing device-related SAEs. \*\*Western Ontario and McMaster Universities Osteoarthritis Pain Index. Scale: 0-20, where a lower score represents a better outcome \*\*\*NRS: Numeric Rating Scale that measures pain from 0 (no pain) to 10 points (worst pain).

    Time frame: 6 Months

  2. Primary Safety Endpoint - Freedom from treatment-related SAEs

    Freedom from treatment-related serious adverse events (SAE) through 6 months following the index procedure (proportions will be compared between Investigational procedure and Control).

    Time frame: 6 Months

Secondary outcomes

  1. Proportion of Responders at 1 Month and 3 Month

    Compare the proportion of responders\* (defined as ≥50% reduction in WOMAC Pain\*\* score and ≥2 point reduction in NRS\*\*\*) between the Investigational procedure and Control at 1 Month and 3 Months. * Non-responders will include subjects experiencing device-related SAEs. \*\*Western Ontario and McMaster Universities Osteoarthritis Pain Index. Scale: 0-20, where a lower score represents a better outcome \*\*\*NRS: Numeric Rating Scale that measures pain from 0 (no pain) to 10 points (worst pain).

    Time frame: 1 Month and 3 Months

  2. Change in mean WOMAC Pain

    Compare mean change from baseline in the Western Ontario and McMaster University Osteoarthritis Index Pain (WOMAC Pain, Scale: 0-20, where a lower score represents a better outcome) between the Investigational procedure and Control at 1 Month, 3 Months and 6 Months.

    Time frame: 1 Month, 3 Months and 6 Months

  3. Change in Numeric Rating Scale (NRS)

    Compare mean decrease in pain (measured using the Numeric Rating Scale (NRS)) between the Investigational procedure and Control at 1 month, 3 months and 6 months. Scale: 0-10, where a lower score means a better outcome.

    Time frame: 1 Month, 3 Months and 6 Months

08

Study locations

8 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 25 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 12, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Dec 2028was Oct 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Dec 2026
Oct 30, 2026
Study completion
Oct 2028→Dec 2028
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Oct 2026→Dec 2026
    Study completion Oct 2028→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06550024
Lead sponsor
CrannMed
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Nov 28, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion